Astrid Bechtold
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Astrid Bechtold has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Bernd Gruhn
Department of Pediatrics, Jena University Hospital, Jena, Germany
1 shared publication - Detlev Schindler
Department of Human Genetics, Biozentrum, University of Würzburg, Würzburg, Germany
1 shared publication - Felix Zintl
Department of Pediatrics, University of Jena, Kochstr. 2, D-07740 Jena, Germany
1 shared publication - Heidemarie Neitzel
Charite Universitatsmedizin Berlin - Campus Virchow-Klinikum
1 shared publication - Holger Hoehn
Institut für Humangenetik, Julius Maximillians Universität Würzburg, Germany
1 shared publication - Holger Tönnies
Department of Human Genetics, Charité – Campus Virchow-Klinikum, Augustenburger Platz 1, Humboldt University Berlin, 13353 Berlin, Germany
1 shared publication
Latest Publications
- Open Access
- 15 January 2007
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 2 (1) , 5
Successful bone marrow transplantation in a patient with DNA ligase IV deficiency and bone marrow failure
DNA Ligase IV deficiency syndrome is a rare autosomal recessive disorder caused by hypomorphic mutations in the DNA ligase IV gene (LIG4). The clinical phenotype shows overlap with a number of other rare syndromes, including Seckel syndrome, Nijmegen breakage syndrome, and Fanconi anemia. Thus the clinical diagnosis is often delayed and established by exclusion. We describe a patient with pre- and postnatal growth retardation and dysmorphic facial features in whom the diagnoses of Seckel-, Dubowitz-, and Nijmegen breakage syndrome were variably considered. Cellular radiosensitivity in the absence of clinical manifestations of Ataxia telangiectasia lead to the diagnosis of DNA ligase IV (LIG4) deficiency syndrome, confirmed by compound heterozygous mutations in the LIG4 gene. At age 11, after a six year history of progressive bone marrow failure and increasing transfusion dependency the patient was treated with matched sibling donor hematopoietic stem cell transplantation (HSCT) using a fludarabine-based conditioning regimen without irradiation. The post-transplantation course was uneventful with rapid engraftment leading to complete and stable chimerism. Now at age 16, the patient has gained weight and is in good clinical condition. HSCT using mild conditioning without irradiation qualifies as treatment of choice in LIG4-deficient patients who have a matched sibling donor.
- 15 January 2007
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 2 (1) , 5
Open AccessSuccessful bone marrow transplantation in a patient with DNA ligase IV deficiency and bone marrow failure
DNA Ligase IV deficiency syndrome is a rare autosomal recessive disorder caused by hypomorphic mutations in the DNA ligase IV gene (LIG4). The clinical phenotype shows overlap with a number of other rare syndromes, including Seckel syndrome, Nijmegen breakage syndrome, and Fanconi anemia. Thus the clinical diagnosis is often delayed and established by exclusion. We describe a patient with pre- and postnatal growth retardation and dysmorphic facial features in whom the diagnoses of Seckel-, Dubowitz-, and Nijmegen breakage syndrome were variably considered. Cellular radiosensitivity in the absence of clinical manifestations of Ataxia telangiectasia lead to the diagnosis of DNA ligase IV (LIG4) deficiency syndrome, confirmed by compound heterozygous mutations in the LIG4 gene. At age 11, after a six year history of progressive bone marrow failure and increasing transfusion dependency the patient was treated with matched sibling donor hematopoietic stem cell transplantation (HSCT) using a fludarabine-based conditioning regimen without irradiation. The post-transplantation course was uneventful with rapid engraftment leading to complete and stable chimerism. Now at age 16, the patient has gained weight and is in good clinical condition. HSCT using mild conditioning without irradiation qualifies as treatment of choice in LIG4-deficient patients who have a matched sibling donor.